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The Journal of Immunology
b2-Adrenoreceptor Agonist Inhibits Antigen
Cross-Presentation by Dendritic Cells
Julie Herve´,*,† Laurence Dubreil,†,‡ Virginie Tardif,x Mickael Terme,*,† Sylvie Pogu,*,†
Ignacio Anegon,x Bertrand Rozec,{ Chantal Gauthier,{ Jean-Marie Bach,*,† and
Philippe Blancou*,†
Despite widespread usage of b-adrenergic receptor (AR) agonists and antagonists in current clinical practice, our understanding
of their interactions with the immune system is surprisingly sparse. Among the AR expressed by dendritic cells (DC), b2-AR can
modify in vitro cytokine release upon stimulation. Because DC play a pivotal role in CD8+ T cell immune responses, we examined
the effects of b2-AR stimulation on MHC class I exogenous peptide presentation and cross-presentation capacities. We demon-
strate that b2-AR agonist-exposed mature DC display a reduced ability to cross-present protein Ags while retaining their
exogenous peptide presentation capability. This effect is mediated through the nonclassical inhibitory G (Gai/0) protein. Moreover,
inhibition of cross-presentation is neither due to reduced costimulatory molecule expression nor Ag uptake, but rather to impaired
phagosomal Ag degradation. We observed a crosstalk between the TLR4 and b2-AR transduction pathways at the NF-kB level.
In vivo, b2-AR agonist treatment of mice inhibits Ag protein cross-presentation to CD8+ T cells but preserves their exogenous
MHC class I peptide presentation capability. These findings may explain some side effects on the immune system associated with
stress or b-agonist treatment and pave the way for the development of new immunomodulatory strategies. The Journal of
Immunology, 2013, 190: 3163–3171.
L
arge amounts of catecholamines are released during
stress and physical activity from postganglionic ad-
renergic fibers and adrenal glands following activation
of the sympathetic nervous system (SNS). The SNS principal neu-
rotransmitters are norepinephrine (NE) and epinephrine (E) that
bind both a- (subtypes a1 and a2) and b-adrenergic receptors (AR)
(subtypes b1, b2, and b3). Modulation of the adrenergic system
has been successful in many diseases, making b-adrenergic mod-
ulators among the best selling drugs in the world. However, their
effects on the immune system have been questioned for different
pathologies (1, 2).
AR are expressed by many cell types throughout the body,
including immune cells. Many authors have documented that
b-AR agonists (referred to as b-agonists) display a deep impact
on T and B cell functions both in vitro and in vivo (reviewed in
Ref. 3). In particular, catecholamines induce elevation in the
number of circulating lymphocytes both in humans (4) and mice
(5). The global effect of b-agonists on immunity was mainly
studied by chemically depleting natural catecholamine stocks
using 6-hydroxydopamine, which results in increased innate
immune responses against bacteria (6), increased adaptive immune
responses against virus (7), and decreased immune responses against
Gram-positive bacteria (7–9). Additionally, surgical removal of
the ocular sympathetic nerve affects the generation and main-
tenance of immune privilege in the eye (10). However, although
these reports strongly suggest that the SNS regulates the mag-
nitude and quality of immune responses via AR agonists, the
molecular and cellular basis of this phenomenon remain un-
clear.
Conflicting results were obtained regarding AR expression on
immune cells (11). Concerning APC, the effect of AR agonists is
being revealed. AR (a1, a2, b1, b2) stimulation of macrophages
decreases their phagocytic activity (12) and TNF-a secretion (13)
and increases apoptosis (14). As APC, dendritic cells (DC) appear
to be uniquely specialized for cross-presentation with the capacity
to acquire exogenous proteins, process them into peptide, load and
display MHC class I (MHC-I)/peptide complexes on their surface,
and prime naive CD8+ T cells. Interestingly, bone marrow–derived
DC (bmDC) and splenic DC express b2-AR receptor mRNA (7,
15). Similar to macrophages, DC are sensitive to AR stimulation,
which modifies their cytokine secretion (16), migration capa-
bilities (17), and Ag uptake (18) via the b2, a1b subtype, and a2-
AR, respectively. Recently, it was demonstrated that b2-AR
blocking enhances antiviral CD8+ T cell responses, supporting
a chronic effect of the b2-AR on immune responses (7). More-
over, deletion of the adrenergic system by chemical sympathec-
tomy was associated to an enhanced cross-presentation capacity of
CD11c+CD8a+ DC (7). However, we do not know whether b2-AR
agonists can directly modify cross-presentation capabilities of DC.
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In this study, we sought to determine the effects of in vitro and
in vivo b2-AR stimulation on cross-presentation of Ag by DC and
on ensuing Ag-specific CD8+ T cell responses using both phar-
macological and genetic approaches. We also investigated the
effects of b2-AR stimulation on the steps involved in cross-
presentation, including Ag uptake and processing. Collectively,
our findings provide new insights into molecular and cellular
mechanisms by which b-agonist impairs Ag-specific immune re-
sponses by interfering with cross-presentation by DC, a process
with broad implications in many diseases.
Materials and Methods
Chemicals
LPS Escherichia coli 0111:B4 was purchased from InvivoGen. Salbutamol
hemisulfate and pertussis toxin (PTX) originated from Sigma-Aldrich. ICI-
118,551, Rp-cAMP, NF-449, forskolin, and KT 5720 came from Tocris
Biosciences. PTX, Rp-AMPc, NF-449, forskolin, and KT 5720 were, re-
spectively, used at 2 mg/ml (19), 300 mM (20), 30 mM (21), 10 mM (22),
and 10 mM (23).
Mice and cells
C57BL/6J, OT-I, and BALB/c mice were originally purchased at The
Jackson Laboratory (Bar Harbor, ME). b2-adrenoreceptor knockout mice
(24) were provided by M. Barrot (Strasbourg University, Strasbourg,
France) and backcrossed for seven generations on the C57BL/6J back-
ground. CL4 mice were provided by R. Liblau. Splenic OT-I and CL4
CD8+ T cells were purified using CD8+ magnetic beads (Miltenyi Biotec).
The B3Z cell line was a gift from A. Savina (INSERM Unite´ 932, Paris,
France). bmDC were derived from C57BL/6J or BALB/c mice as previ-
ously described (25).
DC treatment
After CD11c+ magnetic cell sorting, bmDC were classically treated for 3 h
with LPS (1 mg/ml) with or without salbutamol (1 mM) and with or
without ICI-118,551 (10 mM). For each experiment, supernatants were
collected 24 h afterward and secretion of IL-10 and IL-12 was determined
by ELISA (BD Pharmingen). In parallel, bmDC were analyzed for ex-
pression of CD40, CD80, CD86, and MHC-I and viability (7-amino-
actinomycin D staining) was determined by flow cytometry. We did not
observe any effect of treatment on cell viability (as assessed by 7-ami-
noactinomycin D staining; viability was .95% in all experiments pre-
sented).
In vitro CD8+ T cell activation assays
In vitro CD8+ T cell activation was performed either using OT-I (anti-OVA)
or CL4 (anti-hemagglutinin [HA]) CD8+ T cells.
For OT-I CD8+ T cells, bmDC were incubated either with soluble OVA
(endotoxin-free OVA; Hyglos) (50 mg/ml), OVA-coated beads, or with
the H-2Kb–restricted OVA peptide SIINFEKL (OVA257–264) (1 nM)
(Neosystem/PolyPeptide Laboratories). For CL4 CD8+ T cells, bmDC
were incubated either with an inactivated influenza A PR8 virus (produced
on embryonated chicken eggs provided by Nicolas Escirou, Institut Pas-
teur, Paris, France) or with the H-2Kd–restricted HA peptide IYSTVASSL
(HA512–520) (1 nM) (Neosystem/PolyPeptide Laboratories). For lentiviral
infection, DC were infected in a minimal volume of medium for 1 h with
a lentivirus encoding HA Ag (pRRLSIN.cPPT.PGK/HA.WPRE; Lentiviral
Vector Production Unit, Swiss Institute of Technology, Lausanne, Swit-
zerland) 2 d before coculture. In all cases, after incubation, DC were
thoroughly washed and cocultured with CD8+ T from either OT-I or CL4
transgenic mice or B3Z cells. IL-2 release was measured by ELISA and
proliferation was assessed either using [3H]thymidine incorporation or
CFSE staining.
Assessment of Ag internalization and processing by DC
OVA endocytosis and phagocytosis were determined using Alexa 488-OVA
(Invitrogen) and PE beads (BD Pharmingen), respectively. DC were pulsed
with fluoroprobes for 30 min and chased for 0, 15, 30, and 90 min at 37˚C.
After chase, cells were analyzed by flow cytometry. A control at 4˚C was
included to evaluate the percentage of nonspecific endocytosis or phago-
cytosis.
Intraphagosomal degradation was determined using OVA-coated beads
as previously described (26). DC were pulsed-chased at the indicated times
(0, 30, 60, and 120 min) with OVA-coated beads, washed, immediately
disrupted in lysis buffer, and centrifuged (150 3 g, 4 min, 4˚C). Super-
natants containing beads were collected and stained with a rabbit poly-
clonal anti-OVA (MP Biomedicals) and FITC-coupled anti-rabbit Abs
(Jackson ImmunoResearch). Percentage of degraded OVAwas determined
for each condition. A control tube containing a mixture of protease in-
hibitors (cOmplete tablets; Roche) was included.
Detection of specific peptide/MHC-I complexes on DC
By immunofluorescence, DC were incubated with soluble OVA for 3 h.
Then, immunofluorescence was performed according to a protocol previ-
ously described by Kurts and colleagues (27). Briefly, cells were coincu-
bated with mouse 25-D1.16 mAb (gift from Dr. R.N. Germain), then
revealed using Alexa 568–conjugated donkey anti-murine IgG and coun-
terstained with TO-PRO3 (1 mg/ml; Molecular Probes/Invitrogen). Slides
were observed with a confocal microscope. Mean fluorescence intensity
was measured for each condition in each channel on a total of at least 1500
analyzed cells by conditions.
By flow cytometry, as previously described (27), DC were incubated
with soluble OVA (5 mg/ml) for 16 h, thoroughly washed twice, and in-
cubated with PE-coupled 25-D1.16 mAb (BioLegend) for 30 min on ice.
Cells were then washed and fluorescence intensity was analyzed using
a BD FACSAria. Controls included DC incubated with the OVA peptide
SIINFEKL.
NF-kB immunofluorescence experiments
DC were incubated with anti-p65 NF-kB Ab (SC 372; Santa Cruz Bio-
technology), revealed using Alexa 488–conjugated donkey anti-rabbit IgG,
and cell nuclei were counterstained with TO-PRO3. To evaluate the ratio
of NF-kB protein in the cytoplasm versus nucleus, we developed a macro
using the Nikon instrument software image analysis. The sum intensity of
total NF-kB was measured for image 1, and then the nuclear image (re-
ferred to as image 2) was substracted from the total NF-kB image 1 and the
result of this substraction was identified as image 3, which was quantitated
as the “cytosolic NF-kB fluorescence” sum intensity. The “nuclear NF-kB
fluorescence” sum intensity was determined by substracting total NF-kB
sum intensity (referred to as image 1) to cytosol NF-kB intensity (referred
to as image 3). Finally, mean nuclear intensity was obtained by dividing
nuclear sum intensity by nuclear area determined from image 2. The total
fluorescence mean intensity was determined by dividing total NF-kB sum
intensity by total NF-kB area. Analyses were performed at least on 5000
cells by condition. Pearson’s correlation coefficient calculation as in Ewins
et al. (28) gave comparable results (data not shown).
In vivo cross-presentation assay
Cross-presentation in vivo was assessed in C57BL/6J wild-type (wt) and
b2-AR knockout mice previously injected i.v. with 5 3 106 OT-I CD8+
T cells that were CFSE stained. On day 0, mice received i.p. either OVA
protein (250 mg/mouse) or SIINFEKL peptide (100 mg/mouse) along with
LPS (80 mg/mouse) with or without salbutamol (200 mg/mouse). On day 5,
mice were sacrificed and CD8+ proliferation was assessed by cytometry.
Ex vivo cross-presentation experiments
Cross-presentation by splenic DC was assessed on splenic CD11c+ cells
originating from C57BL/6J mice previously injected i.v. either with OVA
protein (500 mg) or SIINFEKL peptide (100 mg) along with LPS (80 mg)
with or without salbutamol (200 mg). Three to 5 h later, splenic DC were
collected in the presence of brefeldin A as previously described (29).
Splenic DC were cocultured with CFSE-stained OT-I CD8+ T cells and
proliferation was assessed after 40 h.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 4.0
(GraphPad Software). For multiexperimental group analysis, data were
subjected to one-way and two-way ANOVA followed by a post hoc test
(Bonferroni or Tukey multiple comparison test). When experiments were
paired, a Wilcoxon matched paired t test was applied.
Results
b2-AR agonist modifies DC IL-12/IL-10 secretions through
Gai/0 signaling
Using salbutamol (b2-AR agonist) alone or in combination with
ICI-118,551 (b2-AR antagonist), we demonstrated that inhibition
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of IL-12 secretion (86 6 14%, n = 13) and increase of IL-10
secretion (215 6 46%, n = 8) by bmDC were specifically medi-
ated by b2-AR receptor (Fig. 1A). This observation was confirmed
with bmDC originated from b2-AR–deficient mice, which were
insensitive to salbutamol effects on IL-12/IL-10 secretion fol-
lowing TLR4 stimulation (Fig. 1A). Along with this effect, sal-
butamol slightly diminished costimulatory molecule expression
(CD86, CD40) in a b2-AR–dependent fashion (Fig. 1B, Supple-
mental Fig. 1A) but did not change MHC-I molecule expression
(data not shown).
To investigate the b2-AR transduction pathway in DC, we
screened modulatory molecules of the G protein–coupled receptor
transduction pathway for their ability to restore IL-12 secretion
following b2-AR stimulation. Inhibition of either Gs protein by
NF 449 or protein kinase A by KT 5720 and Rp-cAMP did not
restore IL-12 secretion following treatment of DC with salbutamol
(Fig. 1C). Similarly, protein kinase C (Go6983) and phospholipase
A2 (AACOCF3) inhibitors were also tested without success for IL-
12 restoration (Supplemental Fig. 1B). In contrast, PTX restored
both IL-12 and IL-10 secretions (Fig. 1D), supporting a critical
role for the Gai/0 pathway in the effects displayed by b2-AR
agonists on DC. Furthermore, the activation of adenylate cyclase
(AC) using forskolin did not reproduce the effects of salbutamol
on IL-12 secretion, which strengthens the fact that b2-AR–me-
diated effects on DC are not mediated by an increase in intra-
cellular cAMP through AC activation (Fig. 1E).
b2-AR–mediated inhibition of cross-presentation is dependent
on Gai/0
We then investigated whether cross-presentation by DC was di-
rectly affected by salbutamol using the widely used in vitro OVA
cross-presentation assay. Depending on their size, Ag are processed
either through the early endosomal compartment for soluble Ag or
through the phagocytic pathway for particulate Ag (.0.5mm) (30).
LPS-matured bmDC were incubated with soluble OVA, particulate
OVA-coated beads, or OVA peptide and treated using salbutamol
with or without ICI-118,551. Cells were then extensively washed
and cocultured with naive anti-OVA CD8+ T cells (OVA257–264
SIINFEKL, H2-Kb–restricted) isolated form OT-1 TCR transgenic
mice. DC were impaired in their capacity to cross-present soluble
or particulate Ag when treated with the highly specific b2-AR
agonist salbutamol while retaining their exogenous MHC-I/peptide
presentation capabilities toward OVA-specific CD8+ T cells (Fig.
2A). Besides proliferation, IL-2 production was dramatically re-
duced in cross-presentation assays whereas it was conserved for
exogenous MHC-I presentation upon salbutamol treatment of DC
(data not shown). One can argue that the use of high peptide
concentration may hide the potential effect of salbutamol on MHC-
I/peptide presentation capabilities. However, lower peptide con-
centration did not reveal different priming capacities of untreated
versus salbutamol-treated DCs (Fig. 2D). PTX completely restored
cross-presentation (Fig. 2B), once again supporting the coupling of
b2-AR with Gai/0 protein in DC functions.
The massive effect of b2-AR treatment on cross-presentation by
DC cannot be explained by its marginal effect on costimulatory
molecules expression (Fig. 1B, Supplemental Fig. 1A). To test
whether b2-AR inhibition of cross-presentation results from the
decrease in IL-12 secretion (Fig. 1A) or from a decrease in peptide/
MHC-I complex expression at the DC surface, we used the anti-
OVA B3Z hybridoma T cells in an OVA cross-presentation assay.
This cell line is known to be activated exclusively upon OVA257–264
SIINFEKL peptide/MHC-I complex expression (31). When co-
cultured with salbutamol-treated DC, B3Z T cells exhibited inhi-
bition of activation, which is in favor of a decrease in OVA257–264
SIINFEKL peptide/MHC-I complex expression at the DC surface
induced by salbutamol treatment (Fig. 2C, 2D). This phenomenon
FIGURE 1. b2-AR signaling impairs IL-12 secretion and costimulation marker expression but increases IL-10 production by DC in a Gai/0-dependent
fashion. (A and B) bmDC from C57BL/6J wt or b2-AR–deficient mice were either left untreated (iDC), LPS (1 mg/ml) matured, or treated with salbutamol
(1 mM). b2-AR specificity was tested by addition of the b2-AR antagonist ICI-118,551 (10 mM). (C–E) CD11c+ cells were LPS matured and pretreated
with inhibitors for 1 h before being incubated with LPS and salbutamol in at least three independent experiments. IL-12, IL-10 secretion (A, C–E), and
costimulation marker (CD86, CD40) expression (B) were evaluated by ELISA and flow cytometry, respectively, after 24 h culture. Results are either
presented as amount of cytokine released in the supernatant (A) or percentage of secretion as compared with the LPS group (C–E). Each experiment was
performed independently at least three times 6 SEM except in (B) where a representative histogram from cytometric analysis of costimulation marker
(CD86, CD40) expression on DC is presented. For statistical analysis, a one-way ANOVAwas performed. Only significant p values of the different groups
compared with the LPS group are shown. *p , 0.05, **p , 0.01, *** p , 0.001.
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is not restricted to OVA Ag, as cross presentation of HA Ags from
influenza virus is also inhibited following b2-AR stimulation of
DC whereas exogenous peptide presentation is preserved (Fig. 2E).
Interestingly, endogenous MHC-I presentation is also affected, as
salbutamol-treated DC infected with a lentivirus expressing HA Ag
display lower presentation capability to naive CD8+ T cells com-
pared with untreated DC (Fig. 2F).
Collectively, these data establish that signaling through b2-AR
inhibits cross-presentation as well as endogenous presentation
without interfering with exogenous peptide presentation.
b2-AR signaling alters phagosomal degradation
Alteration of exogenous Ag cross-presentation by salbutamol-
treated DC could result from impaired Ag uptake capacities. It
was recently demonstrated that a2-AR stimulation enhances Ag
uptake by DC (18). To investigate this possibility, LPS-treated DC
were incubated with salbutamol and Ag uptake was assessed using
soluble OVA-Alexa 488 and particulate PE beads for endocytic
and phagocytic pathways, respectively. As assessed by flow cy-
tometry, Ag uptake of soluble pH-insensitive OVA fluoroprobe
Alexa 488-OVA was unaffected upon b2-AR stimulation (Fig.
3A). Likewise, salbutamol did not change the ability of DC to
phagocyte 1-mm particulate beads coupled with PE (Fig. 3B).
Moreover, no difference in the percentage of positive cells was
observed at earlier or later time points either with Alexa 488-OVA
or particulate beads coupled with PE (data not shown).
The next step of Ag processing following phagocytosis is protein
degradation that occurs in the early phagosomal compartment (30).
As before, DC were LPS matured, salbutamol treated with or
without b2-AR antagonist before performing a well-standardized
Ag degradation assay (26). OVA degradation at the surface of
phagocytosed beads was significantly affected over time by b2-
FIGURE 2. Salbutamol-treated DC are affected in their cross-presentation but not presentation of peptide capabilities in a Gai/0-dependent fashion.
CD11c+-sorted bmDC were left untreated (iDC), LPS matured with (LPS plus salbutamol group) or without (LPS group) b2-AR agonist for 3 h. (A) For
each condition, CD11c+-sorted bmDC derived from C57/B6J mice were either coincubated with soluble OVA protein, particulate OVA-coated beads, or H2-
Kb–restricted OVA257–264 peptide (SIINFEKL), thoroughly washed, and cocultured with anti-OVA CD8
+ T cells from OT-I mice. b2-AR specificity was
tested by addition of b2-AR antagonist (ICI-118,551). Radioactive thymidine incorporation was evaluated 36 h later for 18 h. One representative ex-
periment out of three is presented. (B) CD11c+ bmDC from C57BL/6J were pretreated with PTX (Gai/0 inhibitor) for 1 h before being treated and loaded
with soluble OVA protein as described above. Radioactive thymidine incorporation was evaluated as in (A). (C and D) CD11c+ bmDC from C57BL/6J mice
were coincubated with soluble OVA protein (C) or SIINFEKL peptide (D) as described above, then thoroughly washed and cocultured with anti-OVA B3Z
CD8+ T cell hybridoma. IL-2 secretion was evaluated after 24 h culture. (E) CD11c+-sorted bmDC derived from BALB/c mice were either incubated with
HA Ags (inactivated influenza H1N1 PR8 virus produced on embryonated eggs) or H2-Kd–restricted HA512–520 peptide for 3 h, thoroughly washed, and
cocultured with anti-HA CD8+ T cells isolated from CL4 TCR transgenic mice (36). Radioactive thymidine incorporation was evaluated as in (A). (F)
CD11c+-sorted bmDC derived from BALB/c mice were infected either with an inactivated or a fully infectious lentivirus expressing HA Ag and cocultured
2 d later with anti-HA CD8+ T cells isolated from CL4 TCR transgenic mice. Uninfected or H2-Kd–restricted HA512–520 peptide-loaded DC were used as
negative or positive controls, respectively. The mean value 6 SEM of one representative experiment performed in triplicates out of at least three is
presented for (A) and (C)–(E), and two for (B) and (F). For statistical analysis a one-way ANOVAwas performed. Only significant p values of the LPS plus
salbutamol group compared with LPS group are shown. ***p , 0.001.
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AR stimulation (Fig. 3C) whereas MHC-I Ag expression was
unaffected (data not shown), demonstrating that phagosomal deg-
radation was partially inhibited by b2-AR signaling. This effect
on LPS-matured DC was reversed using b2-AR antagonist
ICI-118,551.
Endosomal and phagosomal pathways can lead to cytosolic
release of Ag fragments that are further processed by the protea-
some before being either imported to the endoplasmic reticulum or
reimported back to phagosomal or endosomal compartments es-
sentially through TAP-mediated translocation (30). We looked for
modulation of proteasomal activity following b2-AR stimulation
of DC using a Proteasome-Glo cell-based assay as a homoge-
neous, luminescent assay that measures the chymotrypsin-like,
trypsin-like, and caspase-like activities associated with the protea-
some complex in cultured cells. b2-AR stimulation of bmDC did
not affect any of the three proteasome activities tested after 1, 2, or
4 h incubation (Supplemental Fig. 2).
Taking advantage of the 25D1.16 Ab that specifically stains
OVA-derived peptide bound to MHC-I H-2Kb (Supplemental Fig.
3A), we quantified the amount of MHC-I/peptide complexes in
different conditions (Fig. 4A). We found that peptides loaded on
MHC-I molecules following Ag processing were reduced in
salbutamol-treated DC as compared with untreated DC, probably
due to lower OVA degradation efficiency in b2-AR agonist-treated
DC. Moreover, using flow cytometry analyses with the 25D1.16
Ab, we demonstrated that surface OVA-derived peptide bound to
MHC-I H-2Kb was also decreased by salbutamol treatment (Fig.
4B).
Collectively, these data demonstrate that b2-AR stimulation of
matured DC affects phagosomal degradation, which may con-
tribute to decreased MHC-I/peptide complex membrane expres-
sion.
Cross-talk between TLR4 and b2-AR occurs at the NF-kB level
NF-kB is one of the major transcriptional factors activated during
TLR4-induced DC maturation process leading to proinflammatory
cytokine release. To investigate whether b2-AR signaling affects
NF-kB activation following TLR4 stimulation, we performed im-
munofluorescence assays on untreated and salbutamol-treated
cells. Data showed that the nuclear translocation of both p65
(Fig. 5) and p50 (Supplemental Fig. 3B) NF-kB subunits were
significantly and specifically inhibited by salbutamol.
In vivo cross-presentation is inhibited by b2-AR signaling
We next investigated whether b2-AR signaling affects in vivo
cross-presentation. Toward this aim, C57BL/6J recipient mice
were injected with OT-I TCR transgenic T cells expressing
CD45.1 congenic marker and immunized with OVA peptide
SIINFEKL or soluble OVA in addition or not with salbutamol
treatment. The proportion of OT-I donor cells was strongly de-
creased in salbutamol-treated compared with untreated mice in
cross-presentation group (Fig. 6A, Supplemental Fig. 4A). In
contrast, CD8+ T cell expansion to peptide was not inhibited (Fig.
6B, Supplemental Fig. 4A). Importantly, note that inhibition of
CD8+ T cell expansion following salbutamol treatment is specif-
ically mediated by b2-AR, as b2-AR–deficient mice did not show
any inhibition of in vivo OVA protein immune response (Fig. 6C).
To investigate whether reduced cross-presentation of OVA by
salbutamol-treated DC resulted in an inhibited proliferation of
specific CD8+ T cells as observed in vitro, we transferred CFSE
FIGURE 3. Salbutamol treatment does not affect Ag uptake but reduces phagosomal Ag degradation. CD11c+ bmDC were treated with LPS with or
without salbutamol or antagonist for 3 h, as described in Fig. 1. Flow cytometric analysis was either performed during the chase phase after a 30 min pulse
with Alexa 488-OVA–coupled protein (A) or directly after incubation with PE-coupled beads (B). Phagocytic degradation was kinetically determined after
staining with anti-OVA Ab following a 30 min pulse period with OVA bead–coupled protein (C). A 4˚C (A, B) or protease inhibitory mixture (PIC) (C)
control was included at each time point to evaluate the percentage of nonspecific endocytosis, phagocytosis, or proteolysis. All flow cytometric graphs are
representative of three (B), four (C), or five (A) independent experiments. For (A) and (B), a paired t test was applied between LPS and LPS plus salbutamol
groups (none of which reached significance). Error bars represent SEM. For (C) a two-way ANOVAwas performed to compare replicate means of the LPS
plus salbutamol condition to the LPS condition [all tests are not significant for all time points, except in (C), where *p , 0.05 at 120 mn].
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loaded CD45.1+CD8+ T cells from OT-I mice and followed CFSE
dilution in donor C57BL/6J mice 5 d after immunization (Fig.
6D). Most donor cells in untreated mice had undergone more than
five divisions whereas less than half of them had divided as much
in salbutamol-treated mice. This strongly suggests that the defect
in CD8+ T cell expansion was due to a defect of Ag cross-
presentation by DC rather than to an increase in apoptosis-
induced cell death or trapping of CD8+ cells into tissue.
To rule out a potential direct effect of salbutamol on CD8+ T cells,
cardiovascular system, or metabolism rather than a direct effect on
DC, we isolated splenic CD11c+ cells 3–5 h following OVA peptide
or protein immunization and salbutamol treatment. These cells were
in vitro cocultured with CFSE-loaded naive CD8+ T cells from OT-I
mice for 36 h. As observed in vivo, ex vivo stimulation of anti-OVA
CD8+ T cells was decreased when mice were immunized with OVA
protein and treated with salbutamol as compared with untreated
control (Fig. 7). As previously observed, peptide immunization was
as efficient to prime CD8+ T cells in salbutamol-treated compared
with untreated mice (Fig. 7) even when nonsaturating peptide doses
were used (Supplemental Fig. 4B).
Taken together, these results show that salbutamol inhibits in
vivo cross-presentation by DC while retaining their exogenous
peptide presentation capacities.
Discussion
Cross-presentation is often needed for the induction of CD8+ T cell
responses and is critical to many immune mechanisms. However,
ensuing CD8+ T cell priming depends on environmental context.
FIGURE 4. Salbutamol inhibits MHC-I/
peptide complex formation. CD11c+ bmDC
were treated as described in Fig. 1 for 3 h in
the presence of soluble OVA protein and
then either fixed, permeabilized, and stained
with 25-D1.16 Ab (A) or directly stained
with 25-D1.16 Ab and processed for flow
cytometry analysis (B). Slides were ana-
lyzed by confocal microscopy. (A) Repre-
sentative images are presented for the
different conditions. (a), iDC; (b), LPS; (c),
LPS1 salbutamol; (d), LPS1 salbutamol1
ICI 118,551; (e), LPS 1 ICI 118,551. Quan-
tification of immunofluorescence of three in-
dependent experiments is also reported
(bottom right). (B) A representative flow
cytometry profile out of two independent
experiments performed is presented. For
statistical analysis a one-way ANOVA was
performed. Scale bar, 10 mm. Error bars
represent SEM. Only significant p values
are shown. **p , 0.01, ***p , 0.001.
FIGURE 5. b2-AR agonist affects NF-kB translocation to the nucleus. CD11c+ bmDC were treated as described in Fig. 1 for 30 min, fixed, per-
meabilized, and stained using anti-p65 NF-kB Ab. NF-kB p65 nuclear translocation was analyzed by laser confocal microscopy. A representative image is
shown in (a)–(e). (a), iDC; (b), LPS; (c), LPS plus salbutamol; (d), LPS plus salbutamol plus ICI-118,551; (e), LPS plus ICI-118,551. Quantification of
immunofluorescence of three independent experiments is shown in the graph (bottom right). For statistical analysis a one-way ANOVA was performed.
Scale bar, 10 mm. Error bars represent SEM. Only significant p values are shown. *p , 0.05.
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Codelivery of inflammatory signals along with Ag by DC leads to
cytotoxic CD8+ T cell generation whereas the absence of in-
flammatory signals leads to tolerized T cells. Modulating the
initial steps of cross-presentation may be important, as it may help
us to increase or prevent CD8+ T cell activation. In the present
study, we demonstrate that b2-AR signaling inhibits in vitro and
in vivo cross-presentation by DC through the Gi protein pathway.
Interestingly, DC express b2-AR at their surface (7, 15) and
their stimulation by b-agonists leads to modification of their cy-
tokine secretion profile (18, 19). The G protein–coupled receptor
b2-AR was initially considered to be exclusively associated to Gs,
thus increasing AC activity. However, it has recently become
apparent that b-AR are also capable of transducing other signaling
processes than those associated with the formerly recognized
cAMP-related pathways. Studies have shown that some aspects of
signaling via b-AR are inhibited by PTX, indicating that they
might be mediated through Gi proteins (32). In this study, we
demonstrate that b2-AR inhibition of IL-12 secretion and cross-
FIGURE 6. Salbutamol treatment of mice inhibits Ag immune response. C57BL/6J wt (A, B, D) or b2-AR2/2 (C) mice received 4–8 3 106 anti-OVA
CD8+ T cells i.v. from OT-I CD45.1+ mice at day 0. The day after, all mice (A–D) were challenged with LPS (80 mg i.p./mouse) with or without salbutamol
treatment (200 mg i.p./mouse), and immunized either with OVA protein (250 mg i.p./mouse) (A, C, D) or OVA peptide SIINFEKL (100 mg i.p./mouse) (B).
Then, mice were either followed for 1 mo (A–C) or sacrificed at day 5 (D). (D) Histograms of CD8 CD45.1 double-positive spleen cells are presented. The
results shown are representative of at least three independent experiments with at least two animals per group for (A), (B), and (D) and two for (C). Error
bars represent SEM. For (A)–(C) a two-way ANOVAwas performed [all tests are not significant for all time points, except in (A), where **p , 0.01 for one
time point].
FIGURE 7. Salbutamol treatment
of mice inhibits splenic DC cross-
presentation capabilities. C57BL/6J
were challenged with LPS (80 mg
i.p./mouse) plus OVA protein (500
mg i.p./mouse) or OVA peptide
SIINFEKL (100 mg i.p./mouse) and
were treated or not with salbutamol
(200 mg i.p./mouse) the same day.
Four hours after immunization,
CD11c+ cells from the spleen were
sorted out and cocultured with
CFSE-loaded anti-OVA CD8+ T cells
from OT-I mice. CFSE staining was
assessed after 36 h culture. A repre-
sentative flow cytometry analysis and
quantification of divided cells and
IL-2 production are reported in (A),
(B), and (C), respectively. The results
shown are representative of three in-
dependent experiments with at least
three animals per group.
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presentation is Gi-dependent. However, it does not disqualify the
Gs signaling pathway, as it has been suggested that both a1- and
b2-AR are able to switch their G protein–coupling specificity
from Gs to Gi due to phosphorylation of the receptor by protein
kinase A (33, 34). This new Gs/Gi switch-related aspect of b-AR
signaling is Gi protein mediated and leads to activation of MAPKs
(33, 34). In our case, this switch can be excluded concerning the
effect of b2-AR on IL-12 release because Gs pathway modulators
(forskolin, NF449, Rp-cAMP, and KT5720) did not restore IL-12
secretion.
We show that b2-AR stimulation inhibits transcription factor
NF-kB translocation to the nucleus. However, NF-kB in matured
DC is essential for at least three aspects of Ag-presenting function:
upregulation of costimulatory molecules such as CD80, CD86, and
CD40, immunostimulatory cytokines such as IL-12, and cross-
presentation (35). From our data, we infer that the inhibition of
nuclear NF-kB translocation by b2-AR stimulation may explain all
the effects on DC function observed following salbutamol treat-
ment both in vitro and in vivo. The link between b-AR, the NF-kB
pathway, and cell function is not new in immune cells. b-AR
also modulate the NF-kB pathway in macrophages/monocytes
and lymphocytes. b-AR agonists inhibit NF-kB translocation and
cytokine production in LPS-stimulated macrophages (36, 37) and
in PMA/ionomycin activated human CD3+ T cells (38). However,
signaling pathways in macrophages and DC seems very different,
being cAMP-dependent for the former (37) but cAMP-independent
for the latter. The link between NF-kB and b2-AR is still missing,
but it was recently suggested that IkB inhibitory function could be
upregulated by decreased interaction with b-arrestin-2 after b2-AR
stimulation (39).
Our observation that in vitro cross-presentation of exogenous
OVA by DC was reduced by .80% after exposure to b2-AR
agonist indicates that a defect occurs within a subcellular process
involved in this pathway. This observation is not limited to ex-
ogenous Ags, as endogenous presentation of Ags is also affected
by salbutamol treatment (Fig 2F). Whereas soluble and particulate
Ag uptakes are unaffected by b2-AR stimulation on DC, phago-
somal Ag processing is significantly reduced as compared with
untreated cells. Some authors have shown that Ag release kinetics
in the phagosome are critical to cross-presentation efficiency (40).
This delay in phagosomal degradation may be related to various
effects of b2-AR activation on DC function, one of which is
proteasome activity. However, we found that proteasome activity
of salbutamol-treated DC was comparable to untreated DC. Other
hypotheses include the effect of b2-AR stimulation on the regu-
lation of phagosomal pH or protease activities. Interestingly,
presentation of endogenously expressed Ags is also impaired,
suggesting an additional yet unknown effect of b2-AR stimu-
lation on protein cross-presentation.
To our knowledge, this is the first study describing a b2-adre-
noreceptor–dependent inhibition of cross-presentation. We used
experimental OVA and HA systems. In vivo, cross-presentation
can result from processing of dead cells, apoptotic bodies, or
heat shock protein–associated Ags. This cross-presentation path-
way is crucial for tumor-associated Ag presentation or during
bacterial or viral infection. Interestingly, a multitude of factors
have been identified that influence whether tolerance or immunity
is established against cell-associated Ags. Among these factors are
how cells are dying, the recognition and uptake by phagocytic
cells, and the resulting microenvironment. The microenvironment
may possibly include adrenergic innervation. The impact of b2-
AR signaling on cell-associated Ags needs to be further addressed
along with the mechanisms involved, which may be different from
those described in this paper.
Although the in vivo modulation of cross-presentation remains
unclear, there is evidence for a positive effect of inflammatory
stimuli (41, 42) upon engagement of TLRs that modulates endo-
cytosis (43). Many authors have suggested that stress may regulate
immune responses (44). The effect of stress on the immune system
is not only glucorticoid-mediated but also adrenergic-mediated
(45, 46). Both systems have shown a capacity to modulate the
cross-presentation capability of DC (7, 47, 48), consistent with the
deleterious effect of chronic stress on immune responses. How-
ever, b-agonists and antagonists are among the most widely used
drugs in clinical practice for a number of distinct pathologies,
including heart failure, hypertension, asthma, and migraines. To
our knowledge, our study demonstrates for the first time that ad-
ministration of exogenous b2-AR agonist impairs CD8+ priming
by cross-presenting DC in mice. However, Panina-Bordignon
et al. (36) showed more that a decade ago that human DC, similar
to mouse DC, are impaired in IL-12 secretion upon salbutamol
treatment. We can reasonably speculate that b-agonist treatment
would also affect cross-presentation in human DC and that the
impact of administered exogenous b-agonists on the immune
system was underestimated. These results also provide the proof
of concept that b2-agonists may represent a new way for ma-
nipulating the immune system.
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